{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:26:13Z","timestamp":1785403573509,"version":"3.56.0"},"reference-count":86,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Left ventricular hypertrophy (LVH) is a not uncommon finding on cardiac imaging, seen in 10\u201320% of adults. LVH can represent a response to a physiological load on the heart (either by athletic training, hypertension, or structural heart issues) or it can represent a primary pathology (e.g. infiltrative disorders, including cardiac amyloidosis and sarcoidosis) or familial\/genetic conditions (e.g. hypertrophic cardiomyopathy). LVH is an independent risk factor for adverse cardiovascular events, regardless of its etiology. In this review, we survey the etiologies, clinical approach, and use of multimodality imaging in those with LVH.<\/jats:p>","DOI":"10.15420\/usc.2024.65","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:39:44Z","timestamp":1779705584000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic Approach to Left Ventricular Hypertrophy: A Review"],"prefix":"10.15420","author":[{"given":"Sukriti","family":"Banthiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Agrawal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xjacd83","id-type":"ROR","asserted-by":"publisher"}],"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1189-4199","authenticated-orcid":false,"given":"Stephen","family":"Pan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03fcgva33","id-type":"ROR","asserted-by":"publisher"}],"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari S","family":"Naidu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03fcgva33","id-type":"ROR","asserted-by":"publisher"}],"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Stewart MH, Lavie CJ, Shah S, et al. Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis 2018;61:446\u201355. https:\/\/doi.org\/10.1016\/j.pcad.2018.11.002; PMID:\u00a030408469.","DOI":"10.1016\/j.pcad.2018.11.002"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Richey PA, Brown SP. Pathological versus physiological left ventricular hypertrophy: a review. J Sports Sci 1998;16:129\u201341. https:\/\/doi.org\/10.1080\/026404198366849; PMID:\u00a09531002.","DOI":"10.1080\/026404198366849"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bluemke DA, Kronmal RA, Lima JAC, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;52:2148\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2008.09.014; PMID:\u00a019095132.","DOI":"10.1016\/j.jacc.2008.09.014"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Morganroth J, Maron BJ. The athlete\u2019s heart syndrome: a new perspective. Ann N Y Acad Sci 1977;301:931\u201341. https:\/\/doi.org\/10.1111\/j.1749-6632.1977.tb38259.x; PMID:\u00a0145202.","DOI":"10.1111\/j.1749-6632.1977.tb38259.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Naylor LH, George K, O\u2019Driscoll G, Green DJ. The athlete\u2019s heart: a contemporary appraisal of the \u201cMorganroth hypothesis\u201d. Sports Med 2008;38:69\u201390. https:\/\/doi.org\/10.2165\/00007256-200838010-00006; PMID:\u00a018081368.","DOI":"10.2165\/00007256-200838010-00006"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wasfy MM, Weiner RB, Wang F, et al. Endurance exercise-induced cardiac remodeling: not all sports are created equal. J Am Soc Echocardiogr 2015;28:1434\u201340. https:\/\/doi.org\/10.1016\/j.echo.2015.08.002; PMID:\u00a026361851.","DOI":"10.1016\/j.echo.2015.08.002"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Di Gioia G, Ferrera A, Mango F, et al. The spectrum of eccentric left ventricular hypertrophy in endurance sports disciplines. Int J Cardiovasc Imaging 2025;41:1407\u201322. https:\/\/doi.org\/10.1007\/s10554-025-03430-w; PMID:\u00a040419828.","DOI":"10.1007\/s10554-025-03430-w"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cuspidi C, Sala C, Negri F, et al. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 2012;26:343\u20139. https:\/\/doi.org\/10.1038\/jhh.2011.104; PMID:\u00a022113443.","DOI":"10.1038\/jhh.2011.104"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Chu HW, Hwang IC, Kim HM, et al. Age-dependent implications of left ventricular hypertrophy regression in patients with hypertension. Hypertens Res 2024;47:1144\u201356. https:\/\/doi.org\/10.1038\/s41440-023-01571-w; PMID:\u00a038238511.","DOI":"10.1038\/s41440-023-01571-w"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(06)69208-8; PMID:\u00a016980116.","DOI":"10.1016\/S0140-6736(06)69208-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Gonzales H, Douglas PS, Pibarot P, et al. Left ventricular hypertrophy and clinical outcomes over 5 years after TAVR: an analysis of the PARTNER trials and registries. JACC Cardiovasc Interv 2020;13:1329\u201339. https:\/\/doi.org\/10.1016\/j.jcin.2020.03.011; PMID:\u00a032499024.","DOI":"10.1016\/j.jcin.2020.03.011"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Devabhaktuni SR, Chakfeh E, Malik AO, et al. Subvalvular aortic stenosis: a review of current literature. Clin Cardiol 2018;41:131\u20136. https:\/\/doi.org\/10.1002\/clc.22775; PMID:\u00a029377232.","DOI":"10.1002\/clc.22775"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Maurer MS, Elliott P, Comenzo R, et al. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357\u201377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024438; PMID:\u00a028373528.","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Oerlemans MIFJ, Rutten KHG, Minnema MC, et al. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J 2019;27:525\u201336. https:\/\/doi.org\/10.1007\/s12471-019-1299-1; PMID:\u00a031359320.","DOI":"10.1007\/s12471-019-1299-1"},{"key":"ref14","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2021;42:1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072; PMID:\u00a033825853."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008;31:372\u20139. https:\/\/doi.org\/10.1183\/09031936.00075307; PMID:\u00a017959635.","DOI":"10.1183\/09031936.00075307"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015;131:624\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.011522; PMID:\u00a025527698.","DOI":"10.1161\/CIRCULATIONAHA.114.011522"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Rosenbaum AN, Kolluri N, Elwazir MY, et al. Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease. Int J Cardiol 2021;335:66\u201372. https:\/\/doi.org\/10.1016\/j.ijcard.2021.04.022; PMID:\u00a033878372.","DOI":"10.1016\/j.ijcard.2021.04.022"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.605; PMID:\u00a027443438.","DOI":"10.1016\/j.jacc.2016.03.605"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Niemel\u00e4 M, Uusitalo V, P\u00f6yh\u00f6nen P, et al. Incidence and predictors of atrial fibrillation in cardiac sarcoidosis: a multimodality imaging study. JACC Cardiovasc Imaging 2022;15:1622\u201331. https:\/\/doi.org\/10.1016\/j.jcmg.2022.02.025; PMID:\u00a036075623.","DOI":"10.1016\/j.jcmg.2022.02.025"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Darda S, Zughaib ME, Alexander PB, et al. Cardiac sarcoidosis presenting as constrictive pericarditis. Tex Heart Inst J 2014;41:319\u201323. https:\/\/doi.org\/10.14503\/THIJ-13-3208; PMID:\u00a024955053.","DOI":"10.14503\/THIJ-13-3208"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Aronow WS. Management of cardiac hemochromatosis. Arch Med Sci 2018;14:560\u201368. https:\/\/doi.org\/10.5114\/aoms.2017.68729; PMID:\u00a029765443.","DOI":"10.5114\/aoms.2017.68729"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gulati V, Harikrishnan P, Palaniswamy C, et al. Cardiac involvement in hemochromatosis. Cardiol Rev 2014;22:56\u201368. https:\/\/doi.org\/10.1097\/CRD.0b013e3182a67805; PMID:\u00a024503941.","DOI":"10.1097\/CRD.0b013e3182a67805"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dabestani A, Child JS, Perloff JK, et al. Cardiac abnormalities in primary hemochromatosis. Ann N Y Acad Sci 1988;526:234\u201344. https:\/\/doi.org\/10.1111\/j.1749-6632.1988.tb55509.x; PMID:\u00a03389642.","DOI":"10.1111\/j.1749-6632.1988.tb55509.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522\u201336. https:\/\/doi.org\/10.7326\/0003-4819-143-7-200510040-00011; PMID:\u00a016204165.","DOI":"10.7326\/0003-4819-143-7-200510040-00011"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Palka P, Macdonald G, Lange A, Burstow DJ. The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. J Am Soc Echocardiogr 2002;15:884\u201390. https:\/\/doi.org\/10.1067\/mje.2002.118032; PMID:\u00a012221404.","DOI":"10.1067\/mje.2002.118032"},{"key":"ref26","unstructured":"Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2022;79:372\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.002; PMID:\u00a035086660."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Canepa M, Fumagalli C, Tini G, et al. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international sarcomeric human cardiomyopathy registry. Circ Heart Fail 2020;13:e007230. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007230; PMID:\u00a032894986.","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Syed IS, Ommen SR, Breen JF, Tajik AJ. Hypertrophic cardiomyopathy: identification of morphological subtypes by echocardiography and cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 2008;1:377\u201379. https:\/\/doi.org\/10.1016\/j.jcmg.2008.02.008; PMID:\u00a019356452.","DOI":"10.1016\/j.jcmg.2008.02.008"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sherrid MV, Bernard S, Tripathi N, et al. Apical aneurysms and mid\u2013left ventricular obstruction in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2023;16:591\u2013605. https:\/\/doi.org\/10.1016\/j.jcmg.2022.11.013; PMID:\u00a036681586.","DOI":"10.1016\/j.jcmg.2022.11.013"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Li J, Fang J, Liu Y, Wei X. Apical hypertrophic cardiomyopathy: pathophysiology, diagnosis and management. Clin Res Cardiol 2024;113:680\u201393. https:\/\/doi.org\/10.1007\/s00392-023-02328-8; PMID:\u00a037982860.","DOI":"10.1007\/s00392-023-02328-8"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Kitaoka H, Doi Y, Casey SA, et al. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003;92:1183\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2003.07.027; PMID: 14609593.","DOI":"10.1016\/j.amjcard.2003.07.027"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Kottam A, Hanneman K, Schenone A, et al. State-of-the-art imaging of infiltrative cardiomyopathies: a scientific statement from the American Heart Association. Circ Cardiovasc Imaging 2023;16:e000081. https:\/\/doi.org\/10.1161\/HCI.0000000000000081; PMID:\u00a037916407.","DOI":"10.1161\/HCI.0000000000000081"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Maron MS, Xin W, Sims KB, et al. Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy. Am J Med 2018;131:200.e1\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2017.09.010; PMID:\u00a028943383.","DOI":"10.1016\/j.amjmed.2017.09.010"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"D\u2019souza RS, Levandowski C, Slavov D, et al. Danon disease: clinical features, evaluation, and management. Circ Heart Fail 2014;7:843\u201349. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001105; PMID:\u00a025228319.","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Greenberg B, Taylor M, Adler E, et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N Engl J Med 2025;392:972\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2412392; PMID:\u00a039556016.","DOI":"10.1056\/NEJMoa2412392"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Tajan M, Paccoud R, Branka S, et al. The RASopathy family: consequences of germline activation of the RAS\/MAPK pathway. Endocr Rev 2018;39:676\u2013700. https:\/\/doi\/org\/10.1210\/er.2017-00232; PMID: 29924299.","DOI":"10.1210\/er.2017-00232"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Bernardini A, Crotti L, Olivotto I, Cecchi F. Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy. Eur Heart J Suppl 2023;25(Suppl C):C173\u20138. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad074; PMID:\u00a037125268.","DOI":"10.1093\/eurheartjsupp\/suad074"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol 1979;44:401\u201312. https:\/\/doi.org\/10.1016\/0002-9149(79)90388-6; PMID:\u00a0573056.","DOI":"10.1016\/0002-9149(79)90388-6"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Levy D, Labib SB, Anderson KM, et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990;81:815\u201320. https:\/\/doi.org\/10.1161\/01.CIR.81.3.815; PMID:\u00a02137733.","DOI":"10.1161\/01.CIR.81.3.815"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014;114:1089\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2014.07.026; PMID:\u00a025212550.","DOI":"10.1016\/j.amjcard.2014.07.026"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Carroll JD, Gaasch WH, McAdam KPWJ. Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation. Am J Cardiol 1982;49:9\u201313. https:\/\/doi.org\/10.1016\/0002-9149(82)90270-3; PMID:\u00a06459025.","DOI":"10.1016\/0002-9149(82)90270-3"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Pagura L, Porcari A, Cameli M, et al. ECG\/echo indexes in the diagnostic approach to amyloid cardiomyopathy: a head-to-head comparison from the AC-TIVE study. Eur J Intern Med 2024;122:68\u201377. https:\/\/doi.org\/10.1016\/j.ejim.2023.09.026; PMID:\u00a037858441.","DOI":"10.1016\/j.ejim.2023.09.026"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol 2000;85:849\u201353. https:\/\/doi.org\/10.1016\/S0002-9149(99)00879-6; PMID:\u00a010758925.","DOI":"10.1016\/S0002-9149(99)00879-6"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2017;10:e005372. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005372; PMID:\u00a028701526.","DOI":"10.1161\/CIRCIMAGING.116.005372"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Wilde AAM, Semsarian C, M\u00e1rquez MF, et al. European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases. Heart Rhythm 2022;19:e1\u201360. https:\/\/doi.org\/10.1016\/j.hrthm.2022.03.1225; PMID: 35390533.","DOI":"10.1016\/j.hrthm.2022.03.1225"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Haimovich JS, Diamant N, Khurshid S, et al. Artificial intelligence-enabled classification of hypertrophic heart diseases using electrocardiograms. Cardiovasc Digit Health J 2023;4:48\u201359. https:\/\/doi.org\/10.1016\/j.cvdhj.2023.03.001; PMID: 37101945.","DOI":"10.1016\/j.cvdhj.2023.03.001"},{"key":"ref47","unstructured":"Ko WY, Siontis KC, Attia ZI, et al. Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram. J Am Coll Cardiol 2020;75:722\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.030; PMID:\u00a032081280."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Maanja M, Noseworthy PA, Geske JB, et al. Tandem deep learning and logistic regression models to optimize hypertrophic cardiomyopathy detection in routine clinical practice. Cardiovasc Digit Health J 2022;3:289\u201396. https:\/\/doi.org\/10.1016\/j.cvdhj.2022.10.002; PMID:\u00a036589312.","DOI":"10.1016\/j.cvdhj.2022.10.002"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa021332; PMID:\u00a012540642.","DOI":"10.1056\/NEJMoa021332"},{"key":"ref50","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. Circulation 2024;149:e1239\u2013311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250; PMID:\u00a038718139."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Caselli S, Maron MS, Urbano-Moral JA, et al. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol 2014;114:1383\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2014.07.070; PMID:\u00a025217454.","DOI":"10.1016\/j.amjcard.2014.07.070"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Rawlins J, Bhan A, Sharma S. Left ventricular hypertrophy in athletes. Eur J Echocardiogr 2009;10:350\u20136. https:\/\/doi.org\/10.1093\/ejechocard\/jep017; PMID:\u00a019246500.","DOI":"10.1093\/ejechocard\/jep017"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Sheikh N, Papadakis M, Schnell F, et al. Clinical profile of athletes with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2015;8:e003454. https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.003454; PMID:\u00a026198026.","DOI":"10.1161\/CIRCIMAGING.114.003454"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Massarotto RJ, Campbell AJ, Kreiter E, et al. Effects of detraining on left ventricular mass in endurance-trained individuals: a systematic review and meta-analysis. Eur J Prev Cardiol 2024;31:415\u201324. https:\/\/doi.org\/10.1093\/eurjpc\/zwad327; PMID:\u00a037821393.","DOI":"10.1093\/eurjpc\/zwad327"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE\/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1\u201323; quiz 101. https:\/\/doi.org\/10.1016\/j.echo.2008.11.029; PMID:\u00a019130998.","DOI":"10.1016\/j.echo.2008.11.029"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Cuddy SAM, Chetrit M, Jankowski M, et al. Practical points for echocardiography in cardiac amyloidosis. J Am Soc Echocardiogr 2022;35:A31\u201340. https:\/\/doi.org\/10.1016\/j.echo.2022.06.006; PMID:\u00a036064258.","DOI":"10.1016\/j.echo.2022.06.006"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2012-302353; PMID:\u00a022865865.","DOI":"10.1136\/heartjnl-2012-302353"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020;201:e26\u201351. https:\/\/doi.org\/10.1164\/rccm.202002-0251ST; PMID:\u00a032293205.","DOI":"10.1164\/rccm.202002-0251ST"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Moon I, Lee J, Lee SA, et al. Artificial intelligence-enhanced analysis of echocardiography-based radiomic features for myocardial hypertrophy detection and etiology differentiation. Circ Cardiovasc Imaging 2025;18:e017436. https:\/\/doi.org\/10.1161\/CIRCIMAGING.124.017436; PMID:\u00a040143828.","DOI":"10.1161\/CIRCIMAGING.124.017436"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Hwang IC, Choi D, Choi YJ, et al. Differential diagnosis of common etiologies of left ventricular hypertrophy using a hybrid CNN-LSTM model. Sci Rep 2022;12:20998. https:\/\/doi.org\/10.1038\/s41598-022-25467-w; PMID:\u00a036470931.","DOI":"10.1038\/s41598-022-25467-w"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Panichella G, Garofalo M, Sasso L, et al. Artificial intelligence applications in hypertrophic cardiomyopathy: turns and loopholes. Eur Heart J Digit Health 2025;6:853\u201367. https:\/\/doi.org\/10.1093\/ehjdh\/ztaf086; PMID:\u00a040985002.","DOI":"10.1093\/ehjdh\/ztaf086"},{"key":"ref62","unstructured":"US Food and Drug Administration. DEN230003 (Viz HCM). 2023. Available at: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/DEN230003.pdf. Accessed March 31, 2026"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Peterson GE, de Backer T, Contreras G, et al. Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease. Hypertension 2013;62:518\u201325. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.00904; PMID:\u00a023836799.","DOI":"10.1161\/HYPERTENSIONAHA.111.00904"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Schumann CL, Jaeger NR, Kramer CM. Recent advances in imaging of hypertensive heart disease. Curr Hypertens Rep 2019;21:3. https:\/\/doi.org\/10.1007\/s11906-019-0910-6; PMID:\u00a030637533.","DOI":"10.1007\/s11906-019-0910-6"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Hinojar R, Varma N, Child N, et al. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2015;8:e003285. https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.003285; PMID: 26659373.","DOI":"10.1161\/CIRCIMAGING.115.003285"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Domenech-Ximenos B, Sanz-de La Garza M, Prat-Gonz\u00e1lez S, et al. Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes. J Cardiovasc Magn Reson 2020;22:62. https:\/\/doi.org\/10.1186\/s12968-020-00660-w; PMID:\u00a032878630.","DOI":"10.1186\/s12968-020-00660-w"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Writing Committee, Kittleson MM, Ruberg FL, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022; PMID:\u00a036697326.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Rekker LY, Muller SA, Gasperetti A, et al. Diagnostic value of late gadolinium enhancement at cardiovascular magnetic resonance to distinguish arrhythmogenic right ventricular cardiomyopathy from differentials. J Cardiovasc Magn Reson 2024;26:101059. https:\/\/doi.org\/10.1016\/j.jocmr.2024.101059; PMID:\u00a038986843.","DOI":"10.1016\/j.jocmr.2024.101059"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 2020;13:1299\u2013310. https:\/\/doi.org\/10.1016\/j.jcmg.2020.03.010; PMID:\u00a032498919.","DOI":"10.1016\/j.jcmg.2020.03.010"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Kravchenko D, Isaak A, Zimmer S, et al. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis. Eur Heart J Cardiovasc Imaging 2024;25:1451\u201361. https:\/\/doi.org\/10.1093\/ehjci\/jeae154; PMID:\u00a038912832.","DOI":"10.1093\/ehjci\/jeae154"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Cheng RK, Kittleson MM, Beavers CJ, et al. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. Circulation 2024;149:e1197\u2013216. https:\/\/doi.org\/10.1161\/CIR.0000000000001240; PMID:\u00a038634276.","DOI":"10.1161\/CIR.0000000000001240"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Weberling LD, Ochs A, Benovoy M, et al. Machine learning to automatically differentiate hypertrophic cardiomyopathy, cardiac light chain, and cardiac transthyretin amyloidosis: a multicenter CMR study. Circ Cardiovasc Imaging 2025;18:e017761. https:\/\/doi.org\/10.1161\/CIRCIMAGING.124.017761; PMID:\u00a040464070.","DOI":"10.1161\/CIRCIMAGING.124.017761"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Hwang IC, Chun EJ, Kim PK, et al. Automated extracellular volume fraction measurement for diagnosis and prognostication in patients with light-chain cardiac amyloidosis. PLoS One 2025;20:e0317741. https:\/\/doi.org\/10.1371\/journal.pone.0317741; PMID:\u00a039841643.","DOI":"10.1371\/journal.pone.0317741"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Schofield R, Ganeshan B, Fontana M, et al. Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy. Clinical Radiology. 2019;74(2):140-149. doi:10.1016\/j.crad.2018.09.016","DOI":"10.1016\/j.crad.2018.09.016"},{"key":"ref75","unstructured":"Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227\u201332. https:\/\/doi.org\/10.1161\/01.CIR.0000066323.15244.54; PMID:\u00a012707239."},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Maestro-Benedicto A, Vela P, de Frutos F, et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail 2022;24:2367\u201373. https:\/\/doi.org\/10.1002\/ejhf.2658; PMID:\u00a035999650.","DOI":"10.1002\/ejhf.2658"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 2020;142:e7\u201322. https:\/\/doi.org\/10.1161\/CIR.0000000000000792; PMID:\u00a032476490.","DOI":"10.1161\/CIR.0000000000000792"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Elliott P, Schunkert H, Bondue A, et al. Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC council on cardiovascular genomics. Eur Heart J 2025;46:344\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehae747; PMID:\u00a039673718.","DOI":"10.1093\/eurheartj\/ehae747"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Yogasundaram H, Alhumaid W, Dzwiniel T, et al. Cardiomyopathies and genetic testing in heart failure: role in defining phenotype-targeted approaches and management. Can J Cardiol 2021;37:547\u201359. https:\/\/doi.org\/10.1016\/j.cjca.2021.01.016; PMID:\u00a033493662.","DOI":"10.1016\/j.cjca.2021.01.016"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy \u2013 a Heart Failure Society of America practice guideline. J Card Fail 2018;24:281\u2013302. https:\/\/doi.org\/10.1016\/j.cardfail.2018.03.004; PMID:\u00a029567486.","DOI":"10.1016\/j.cardfail.2018.03.004"},{"key":"ref81","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 2022;79:e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012; PMID: 35379503."},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 2016;134:e579\u2013646. https:\/\/doi.org\/10.1161\/CIR.0000000000000455; PMID:\u00a027832612.","DOI":"10.1161\/CIR.0000000000000474"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Van Der Bijl P, Delgado V, Bootsma M, Bax JJ. Risk stratification of genetic, dilated cardiomyopathies associated with neuromuscular disorders: role of cardiac imaging. Circulation 2018;137:2514\u201327. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031110; PMID:\u00a029866775.","DOI":"10.1161\/CIRCULATIONAHA.117.031110"},{"key":"ref84","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on myocardial and pericardial diseases. Eur Heart J 2021;42:1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072; PMID: 33825853."},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Muller SA, Peir\u00f3-Aventin B, Biagioni G, et al. Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. Eur J Heart Fail 2024;26:2025\u201334. https:\/\/doi.org\/10.1002\/ejhf.3339; PMID:\u00a038887861.","DOI":"10.1093\/eurheartj\/ehae666.1985"}],"container-title":["US Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:39:54Z","timestamp":1779705594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":86,"URL":"https:\/\/doi.org\/10.15420\/usc.2024.65","relation":{},"ISSN":["1758-3896","1758-390X"],"issn-type":[{"value":"1758-3896","type":"print"},{"value":"1758-390X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"e06"}}